Abstract

UPDATE NOACS USE IN TREATMENT OF ATRIAL FIBRILLATION A REVIEW ATRICLE

Alifia Risma Fahmi* and Suharjono

Abstract

Atrial fibrillation is a type of cardiac arrhythmia and it associated with increased risk for ischemic stroke. Vitamin K antagonists were used to reduce thromboembolic risk; however, these medications require therapeutic monitoring and increase risk of bleeding. Novel oral anticoagulants (NOACs) were use as alternative to vitamin K antagonists and several studies have showed the benefit of NOAC to decrease clotting as well as the risk of bleeding in over to vitamin K antagonists, such as warfarin. This study has found that NOACs are as effective as warfarin in reducing the risk of stroke through anticoagulation. Also, NOACs have a decreased risk of significant bleeding and other secondary risk effect.

Keywords: NOACs, warfarin, Atrial Fibrillation, anticoagulant, novel oral anticoagulant, vitamin K antagonist.